Media Articles Related to Navelbine (Vinorelbine)
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
Source: Lung Cancer News From Medical News Today [2016.06.02]
The U.S. Food and Drug Administration has approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib).
Stage IIIA non-small cell lung cancer survival rates improved when care includes four specific quality measures
Source: Lung Cancer News From Medical News Today [2016.05.17]
Analysis of data from the National Cancer Data Base (NCDB) demonstrates that the survival rates of patients with Stage IIIA NSCLC who underwent surgery increased more than three-fold for those who...
Lung cancer patients who have surgery live longer
Source: Lung Cancer News From Medical News Today [2016.06.09]
But fewer patients with advanced lung cancer are having surgery.Patients with late-stage, non-small cell lung cancer (NSCLC) who have surgery have better survival rates than those who don't, but...
Lung Cancer: Expanded Alimta Label
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has expanded the indication for the cancer drug pemetrexed injection to act as a maintenance therapy with cisplatin for nonsquamous non-small cell lung cancer.
Published Studies Related to Navelbine (Vinorelbine)
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study. [2011.05]
BACKGROUND/PURPOSE: This study compared front-line treatment with docetaxel or vinorelbine in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Docetaxel has an efficacy comparable to that of vinorelbine as first-line treatment in elderly patients with NSCLC and has an acceptable toxicity profile. The trial was closed prematurely because of low accrual, thus limiting the strength of the conclusions derived. Copyright (c) 2011. Published by Elsevier Inc.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]
BACKGROUND: To evaluate activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naive relapsed breast cancer patients... CONCLUSIONS: Both anthracycline- containing regimens evaluated in the present study seem to be active and with a satisfactory tolerability in anthracycline-naive relapsed breast cancer patients.
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). [2011.04]
BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer... CONCLUSION: Although response rate, PFS and survival were non-different in both groups, toxicity was significantly worse in group B and therefore further investigation of P-Vin is of no value. (c) The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. [2011.03.29]
BACKGROUND: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory... CONCLUSIONS: This randomised phase II trial has revealed comparable results for three gemcitabine-based regimens regarding treatment efficacy and toxicity. Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated patients with metastatic breast cancer.
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. [2011.03]
PURPOSE: This study evaluates the activity and toxicity of the paclitaxel/carboplatin (PC) doublet versus vinorelbine/carboplatin (VC) doublet as second-line treatment in patients who have advanced non-small-cell lung cancer (NSCLC)... CONCLUSIONS: Platinum-based doublets with either paclitaxel or vinorelbine in patients with advanced/metastatic NSCLC pretreated with front-line docetaxel/gemcitabine show comparable efficacy when used in the second-line setting. Copyright (c) 2011. Published by Elsevier Inc.
Clinical Trials Related to Navelbine (Vinorelbine)
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer [Completed]
The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine)
to be used with erlotinib in non-small cell lung cancer.
Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca [Recruiting]
This 2 arms study will assess the efficacy and safety of the Vinorelbine-Docetaxel
combination given as an initial upfront treatment (first line) to all metastatic breast
cancer patients enrolled. Patients having a disease control following initial treatment,
will be randomized to either oral Vinorelbine maintenance arm or Observation arm. The trial
will also compare the efficacy and safety of maintenance oral Vinorelbine versus
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer [Completed]
The purpose of this study is to find out what effects the preoperative combination therapies
of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early
stage HER-2 positive breast cancer.
Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer [Recruiting]
Preoperative Herceptin and Navelbine for Breast Cancer [Active, not recruiting]
The purpose of this study is to find out what effects the preoperative combination therapy
of herceptin and navelbine have on HER-2 positive breast cancer.
Reports of Suspected Navelbine (Vinorelbine) Side Effects
Febrile Neutropenia (10),
Confusional State (8),
Tongue Neoplasm Malignant Stage Unspecified (8),
Neoplasm Progression (6),
Pleural Effusion (6),
Neutropenia (6), more >>